Video

Our team behind the scenes at SXSW | Opening by Joanna Shields, BenevolentAI CEO

In our 5 part series filmed at SXSW, our team showcased how AI can be used to better understand the underlying causes of disease, and redefine the way new medicines are brought to patients.

In this first video, our CEO, Joanna Shields, introduces the Benevolent team and our vision. We brought our Benevolent Team to Texas to share our collective vision of using the power of technology to solve something that truly matters to the world. For us, this means tackling the most challenging and devastating diseases that currently have no cure. We believe our efforts can and will change outcomes for patients.

There are an estimated 9,000 untreated diseases in the world and 300 million people suffering from rare diseases. Developing a treatment and getting it to market takes 10-15 years and costs more than $2.5 billion. After all that, the top ten selling drugs in the market today only work for 30-50% of patients.

Why? Because biology is complicated. The underlying molecular mechanisms, pathways and biological processes specific to a patient needs to be fully understood to effectively diagnose a disease and develop a medicine to treat it.

Humans are limited by the amount of information they can absorb and process. Against a backdrop of >10,000 new scientific papers published daily, and the millions of patents, chemical databases, clinical trials and countless other data sources, it’s almost impossible for scientists to leverage all the existing information to make new discoveries.  While this deluge of data represents a limitation of human comprehension, it lends itself perfectly to machine learning.  

AI can help us uncover relationships between diseases and symptoms, drugs and their effect, the patients that will best respond to treatment and much more. At BenevolentAI, we believe that unconventional thinking combined with purposeful technology can truly make an impact on humanity.  

Watch our team share this example of how we work to do exactly that.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021